4D Biomaterials is the trading name of 4D Medicine Ltd, a company that was spun out from the Universities of Birmingham and Warwick in April 2020.
Our mission is to commercialise a new class of materials – liquid resins that can be printed into solid 3D scaffold implants to help patients recover from major medical procedures. The polycarbonate-urethane based resins, marketed under the tradename 4Degra®, are novel bioresorbable materials with good shape memory, tuneable mechanical and chemical properties and promising tissue-healing performance. The composition of the resins is protected by a family of patents owned by the company.
The company has secured over £1.85m ($2.6m) in equity investment from DSW Ventures, Mercia and SFC Capital and over £300k in grants from Innovate UK. These funds are being used to support development of the 4Degra® resin-ink product range and 3D printed medical device prototypes, in collaboration with 3D printing companies and medical device manufacturers. Our aims are to build a substantial business supplying liquid resins and 3D printed components to medical device manufacturers and ultimately to help improve patient quality of life by accelerating healing and recovery after common surgical procedures